Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib ; day:12 ; month:12 ; year:2018 ; pages:1-9
Targeted oncology ; (12.12.2018), 1-9
- Creator
-
Hochmair, Maximilian J.
Buder, Anna
Schwab, Sophia
Burghuber, Otto C.
Prosch, Helmut
Hilbe, Wolfgang
Cseh, Agnieszka
Fritz, Richard
Filipits, Martin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-018-0612-z
- URN
-
urn:nbn:de:101:1-2019012819070039355838
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hochmair, Maximilian J.
- Buder, Anna
- Schwab, Sophia
- Burghuber, Otto C.
- Prosch, Helmut
- Hilbe, Wolfgang
- Cseh, Agnieszka
- Fritz, Richard
- Filipits, Martin
- SpringerLink (Online service)
Other Objects (12)
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Erfolgreiche Behandlung eines Afatinib-refraktären nicht kleinzelligen Bronchialkarzinoms mit seltenen komplexen EGFR-Mutationen mit Pembrolizumab: ein Fallbericht
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Erfolgreiche Behandlung eines Afatinib-refraktären nicht kleinzelligen Bronchialkarzinoms mit seltenen komplexen EGFR-Mutationen mit Pembrolizumab: ein Fallbericht
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients